** Shares of drugmaker Durect Corp rise 3.8% to $1.1
** U.S. FDA has granted "breakthrough therapy" designation (BTD) to DRRX's treatment for patients with severe alcohol-associated hepatitis (AH)
** AH is an acute form of liver disease associated with long-term heavy alcohol intake, often following a recent period of increased consumption
** Company plans to confirm the efficacy and safety of the treatment candidate, larsucosterol, in a registrational late-stage trial
** BTD is meant to speed up the development and review of drugs to treat a serious condition or unmet medical need
** Including session's gain, stock up more than 80% YTD
(Reporting by Pratik Jain in Bengaluru)
((Pratik.Jain@thomsonreuters.com;))
Comments